Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 119.01 -0.30% -0.36
ALXN closed down 0.3 percent on Tuesday, May 22, 2018, on 37 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical ALXN trend table...

Date Alert Name Type % Chg
May 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
May 22 Spinning Top Other 0.00%
May 22 Multiple of Ten Bearish Other 0.00%
May 22 Inside Day Range Contraction 0.00%
May 22 Down 3 Days in a Row Weakness 0.00%
May 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.30%
May 21 Multiple of Ten Bearish Other -0.30%
May 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.70%
May 18 Narrow Range Bar Range Contraction -1.70%
May 18 NR7 Range Contraction -1.70%

Older signals for ALXN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 149.34
52 Week Low 96.18
Average Volume 2,184,593
200-Day Moving Average 123.2518
50-Day Moving Average 115.1934
20-Day Moving Average 118.0955
10-Day Moving Average 119.856
Average True Range 3.589
ADX 10.51
+DI 22.07
-DI 21.29
Chandelier Exit (Long, 3 ATRs ) 112.713
Chandelier Exit (Short, 3 ATRs ) 116.217
Upper Bollinger Band 125.6285
Lower Bollinger Band 110.5625
Percent B (%b) 0.56
BandWidth 12.757472
MACD Line 1.7707
MACD Signal Line 1.629
MACD Histogram 0.1417
Fundamentals Value
Market Cap 26.56 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 51.52
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 121.74
Resistance 3 (R3) 121.82 120.99 121.29
Resistance 2 (R2) 120.99 120.29 120.95 121.13
Resistance 1 (R1) 120.00 119.87 119.59 119.92 120.98
Pivot Point 119.17 119.17 118.96 119.13 119.17
Support 1 (S1) 118.18 118.47 117.77 118.10 117.04
Support 2 (S2) 117.35 118.05 117.31 116.89
Support 3 (S3) 116.36 117.35 116.74
Support 4 (S4) 116.28